No results found

Check the spelling or try searching for a more general term.

World Glaucoma Congress 2019

World Glaucoma Congress 2019

PROACTIVE GLAUCOMA CARE

Ellex invites you to join us in Melbourne for the World Glaucoma Congress (WGC) 2019, 27-30 March to discuss the proactive care of your glaucoma patients, including the role of the iTrack™ surgical system as an adjunctive MIGS procedure.

ABIC™, ELLEX iTRACK

MIGS INDUSTRY SYMPOSIUM

Performed as a stand-alone procedure or as an adjunct to cataract surgery, experts will discuss ABiC™ in clinical practice, addressing a number of topics such as patient selection and the role of ABiC™ as an adjunct to other MIGS procedures. The synergies of Selective Light Therapy (SLT) and ABiC™ in the glaucoma treatment armamentarium will also be addressed.

FACULTY

Mahmoud A. Khaimi
MD (USA)
Deric deWit
MD (Australia)
Paul Singh
MD (USA)

DATE:
Thursday, 28 March

TIME:
7:30am – 8:30am

VENUE:
Room 217 (Melbourne Convention Center)

MODERATOR:
David Lubeck, MD (USA)

Register your interest Download the invitation

Note: this symposium is affiliated with the official program of WGC 2019.


MIGS MEET THE EXPERT

Join us at the Ellex Exhibit #1-2 to meet a panel of leading MIGS experts to discuss their clinical tips and surgical pearls for ABiC™. Intuitive and efficient, ABiC™ can be performed as a stand-alone procedure, or it can be combined with cataract surgery. ABiC™ can also be used in conjunction with other MIGS devices or treatments — and, as an atraumatic procedure, it does not preclude future treatment options.

Each session will incorporate Wet Labs featuring the Ellex iTrack™ Surgical System. 

FACULTY

Mahmoud A. Khaimi
MD (USA)
Paul Singh
MD (USA)

THURSDAY, 28 MARCH
SESSION 1:
9:45am – 10:15am

SESSION 2:
3.15pm – 3:45pm

FRIDAY, 29 MARCH
SESSION 1:
9:45am – 10:15am

SESSION 2:
3.15pm – 3:45pm

SATURDAY, 30 MARCH
SESSION 1:
9:45am – 10:15am

Register your interest

Note: these sessions are not affiliated with the official program of WGC 2019.

“I have been a practicing glaucoma specialist for over 10 years. The introduction of ABiC has completely changed my glaucoma treatment paradigm. Not only has ABiC proven itself to be highly effective in lowering IOP and reducing medication dependence, it also offers an excellent safety profile. There is no manipulation of the conjunctiva, and the post-op recovery resembles that of cataract surgery.”

Mahmoud A. Khaimi, MD
Dean McGee Eye Institute, University Of Oklahoma


ABiC INDUSTRY WET LAB

Join Ellex for an instructional Wet Lab on ABiC™, hosted as part of the official program of the WGC 2019. Featuring a panel of world-renowned MIGS practitioners, including ABiC™ pioneer Mahmoud A. Khaimi, MD (Dean McGee Eye Institute) the 30-minute Wet Lab will address  best treatment practices for ABiC™.

Upon completion of the Wet Lab, clinicians should be able to: 

  • Identify the anatomical cues that can help guide and orient the ABiC™ procedure i.e. Schlemm’s canal, choroid, scleral spur and Schwalbe’s line.
  • Understand the clinical pearls for the successful pre-operative, intra-operative and post-operative management of patients undergoing ABiC™.
  • Understand the role of ABiC™ in the glaucoma treatment algorithm, relative to MIGS procedures, medications and other surgical approaches
  • Determine patient selection criteria for ABiC™

      FACULTY

      Mahmoud A. Khaimi
      MD (USA)
      Paul Singh
      MD (USA)
      Deric deWit
      MD (Australia)
      David Lubeck
      MD (USA)

      DATE:
      Friday, 29 March

      VENUE:
      Room 111-112 (Melbourne Convention Center)

      SESSION TIMES:
      Session 1:
      8.30am – 9:00am

      Session 2:
      9:00 – 9:30am

      Session 3:
      9:30 – 10:00am

      REGISTER YOUR INTEREST VIA THE WGC WEBSITE

      Note: this event is affiliated with the official program of WGC 2019.


      ABiC™ PHYSICIAN DINNER

      Join your colleagues and leading ABiC™ experts Mahmoud A. Khaimi, MD, David Lubeck, MD, and Paul Singh, MD for an intimate discussion over dinner to address the role of ABiC™, including its adjunctive role with other MIGS options.

      FACULTY

      Mahmoud A. Khaimi
      MD (USA)
      David Lubeck
      MD (USA)
      Paul Singh
      MD (USA)

      DATE:
      Thursday, 28 March

      TIME:
      7:00pm – 9:30pm

      VENUE:
      Rosetta Ristorante
      8, Crown Casino
      Whiteman Street, Southbank

      ROOM:
      Rosetta Room

      Register your interest Download the invitation

      Note: this event is not affiliated with the official program of the WGC 2019.

      ABiC™ FROM ELLEX

      ABiC™ re-establishes the eye’s natural outflow system by accessing, catheterizing and viscodilating the trabecular meshwork, Schlemm’s canal, and the distal outflow system. It is the only ab-interno, canal-based MIGS procedure currently available that comprehensively addresses blockages in the collector channels, flushing the outflow channels without damaging tissue.. Intuitive and efficient, ABiC™ can be performed as a stand-alone procedure, or it can be combined with cataract surgery. ABiC™ can also be used in conjunction with other MIGS devices or treatments — and, as an atraumatic procedure, it does not preclude future treatment options.

      “I have been a practicing glaucoma specialist for over 10 years. The introduction of ABiC has completely changed my glaucoma treatment paradigm. Not only has ABiC proven itself to be highly effective in lowering IOP and reducing medication dependence, it also offers an excellent safety profile. There is no manipulation of the conjunctiva, and the post-op recovery resembles that of cataract surgery.”

      Mahmoud A. Khaimi, MD
      Dean McGee Eye Institute, University Of Oklahoma


      iTRACK™ SURGICAL SYSTEM

      Behind the apparent simplicity of ABiC™ and Canaloplasty is the iTrack™ surgical system. Intelligently designed and meticulously tested across each treatment step, the iTrack™ surgical system comprises the iTrack™ microcatheter, the ViscoInjector™ viscoelastic injector, and the iLumin™ illumination source.

      SLT, SELECTIVE LIGHT THERAPY

      SLT lowers IOP as effectively as medication, has a consistent safety profile, and – best of all – is efficacious at every stage of the glaucoma disease process, making it an invaluable tool in the glaucoma treatment armamentarium. As an added benefit, SLT also eliminates the compliance issues and side effects associated with medications.

      When SLT was first introduced, it was typically used as a secondary therapy in patients with maximum medical therapy. Over time, however, an increasing number of ophthalmologists have started to use SLT earlier in the treatment process. This shift in treatment approach has been supported by a number of studies, including the SLT Med Study by Dr. Katz and colleagues, which showed that SLT achieved the same efficacy as prostaglandins when used as first line treatment.


      SLT: Find the Best Path to Renewed Outflow

      Alongside its role in treating glaucoma, SLT can also provide powerful insight into a glaucoma patient’s pathology, based on the fact that SLT primarily addresses the trabecular meshwork. If SLT successfully lowers IOP it indicates that the primary blockage is located in the trabecular meshwork. In contrast, if SLT does not successfully lower IOP it indicates that the point of outflow resistance resides beyond the trabecular meshwork, either in the canal or distally. The idea that SLT can function both as a highly effective first-line treatment, as well as provide useful inference regarding the patient’s pathology and thereby assist with the selection of future treatment strategies, is a compelling reason to adopt SLT first-line.


      A Restorative Approach with SLT

      Due to its restorative, non-destructive mechanism, SLT does not cause scarring of the trabecular meshwork and helps to keep Schlemm's canal intact – making it the ideal adjunct procedure to MIGS options that target Schlemm’s canal. Argon Laser Trabeculoplasty (ALT), in contrast, causes scarring of Schlemm’s canal and thereby compromises the success of future MIGS procedures.


      SLT and MIGS

      The ability of SLT to maintain the flow through the trabecular meshwork as well as the canal and distal channels means we can maximize the flow through the natural outflow systems as early as possible. That not only lowers pressure, but also primes the area for use of MIGS at a later time. Further, the fact that SLT acts to expand Schlemm’s canal suggests that its mechanism of action complements that of ABiC and hence the two procedures could be used in combination.


      SLT from Ellex

      Ellex’s proprietary SLT technology delivers advanced energy control, a sharp-edged aiming beam and the industry’s fastest firing rate of three shots per second*. It's a capability that's being used every day by thousands of physicians around the world to visualize the trabecular meshwork in greater detail, and to perform procedures faster and with improved accuracy, delivering better patient outcomes - reliably, accurately and safely.

      Preview SLT technology from Ellex at the WGC 2019.


      PROACTIVE GLAUCOMA CARE

      Ellex is at the vanguard of working with physicians to transform outcomes and quality of life for patients with glaucoma. Our leading edge SLT Selective Light Therapy and ABiC™ – our restorative solution for minimally invasive glaucoma surgery, performed with the iTrack™ surgical system – offer the ability to intervene earlier in the treatment of glaucoma, and to treat across the full spectrum of the disease, and thereby enable significant numbers of patients to minimize or obviate the need for medications to control their glaucoma.

      At Ellex, we're proud to be helping to shift the paradigm towards proactive glaucoma care. Visit the Ellex exhibit #1-2 to learn more.

      “My treatment paradigm is to go to SLT as primary therapy, and then use a MIGS procedure like ABiC with the iTrack after that. If the disease progresses, my next steps would be perhaps SLT again, and then maybe some other MIGS, pushing back filtering and tube surgeries to later stages. In this paradigm, medication has fallen to an adjunct in between those treatment stages.”

      Mahmoud A. Khaimi, MD
      Dean McGee Eye Institute, University Of Oklahoma

      Welcome to Ellex Global. Continue to Ellex USA at ellex.comus/
      Let's go!
      This website uses cookies to ensure you get the best experience on our website.
      The cookies do not store any personalised information. Learn More